| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.
|
N Engl J Med
|
2004
|
7.73
|
|
2
|
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
|
Blood
|
2008
|
3.52
|
|
3
|
Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
|
J Clin Oncol
|
2008
|
2.74
|
|
4
|
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
|
Biol Blood Marrow Transplant
|
2011
|
2.63
|
|
5
|
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
2.45
|
|
6
|
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.
|
J Clin Oncol
|
2010
|
2.31
|
|
7
|
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
|
Blood
|
2006
|
2.31
|
|
8
|
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
|
Haematologica
|
2008
|
2.26
|
|
9
|
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
|
Am J Hematol
|
2014
|
2.26
|
|
10
|
Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing.
|
Blood
|
2007
|
2.16
|
|
11
|
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
|
Cancer
|
2009
|
2.15
|
|
12
|
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
|
Biol Blood Marrow Transplant
|
2008
|
1.96
|
|
13
|
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.
|
Transplantation
|
2009
|
1.76
|
|
14
|
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
|
Biol Blood Marrow Transplant
|
2007
|
1.74
|
|
15
|
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
|
Biol Blood Marrow Transplant
|
2002
|
1.71
|
|
16
|
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.
|
Blood
|
2009
|
1.70
|
|
17
|
Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation.
|
Blood
|
2011
|
1.61
|
|
18
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.56
|
|
19
|
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
|
Blood
|
2013
|
1.54
|
|
20
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
|
Biol Blood Marrow Transplant
|
2009
|
1.53
|
|
21
|
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.
|
Blood
|
2010
|
1.50
|
|
22
|
Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.
|
Biol Blood Marrow Transplant
|
2012
|
1.46
|
|
23
|
Simultaneously optimizing dose and schedule of a new cytotoxic agent.
|
Clin Trials
|
2007
|
1.46
|
|
24
|
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.
|
Blood
|
2003
|
1.46
|
|
25
|
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.
|
Blood
|
2004
|
1.42
|
|
26
|
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
|
Biol Blood Marrow Transplant
|
2007
|
1.40
|
|
27
|
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
|
Biol Blood Marrow Transplant
|
2010
|
1.34
|
|
28
|
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation.
|
Br J Haematol
|
2003
|
1.33
|
|
29
|
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
1.33
|
|
30
|
Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation.
|
Blood
|
2013
|
1.31
|
|
31
|
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
|
Biol Blood Marrow Transplant
|
2009
|
1.31
|
|
32
|
Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD.
|
Blood
|
2005
|
1.27
|
|
33
|
Unrelated cord blood transplants in adults with hematologic malignancies.
|
Haematologica
|
2006
|
1.27
|
|
34
|
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
|
Biol Blood Marrow Transplant
|
2013
|
1.25
|
|
35
|
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type.
|
Haematologica
|
2010
|
1.25
|
|
36
|
Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.
|
Blood
|
2012
|
1.22
|
|
37
|
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
|
Blood
|
2006
|
1.19
|
|
38
|
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2013
|
1.15
|
|
39
|
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
|
Biol Blood Marrow Transplant
|
2009
|
1.14
|
|
40
|
A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2009
|
1.14
|
|
41
|
Altered gene expression in busulfan-resistant human myeloid leukemia.
|
Leuk Res
|
2008
|
1.12
|
|
42
|
Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation.
|
Curr Opin Hematol
|
2011
|
1.11
|
|
43
|
Hyperacute GVHD: risk factors, outcomes, and clinical implications.
|
Blood
|
2007
|
1.10
|
|
44
|
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
|
J Clin Oncol
|
2012
|
1.10
|
|
45
|
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
|
Biol Blood Marrow Transplant
|
2011
|
1.09
|
|
46
|
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.
|
Biol Blood Marrow Transplant
|
2011
|
1.06
|
|
47
|
Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation.
|
Br J Haematol
|
2008
|
1.03
|
|
48
|
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
|
Blood
|
2012
|
1.03
|
|
49
|
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
|
Haematologica
|
2009
|
1.02
|
|
50
|
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
|
Blood
|
2010
|
1.01
|
|
51
|
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
|
Cancer
|
2007
|
1.00
|
|
52
|
Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.98
|
|
53
|
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.
|
Blood
|
2008
|
0.96
|
|
54
|
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
|
Leuk Lymphoma
|
2012
|
0.96
|
|
55
|
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
|
Cancer
|
2005
|
0.94
|
|
56
|
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.
|
Curr Opin Oncol
|
2009
|
0.91
|
|
57
|
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters.
|
Blood
|
2004
|
0.89
|
|
58
|
Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit.
|
J Clin Oncol
|
2013
|
0.88
|
|
59
|
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.
|
Biol Blood Marrow Transplant
|
2010
|
0.87
|
|
60
|
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
|
Blood
|
2007
|
0.87
|
|
61
|
Epigenetic therapy in allogeneic hematopoietic stem cell transplantation.
|
Rev Bras Hematol Hemoter
|
2013
|
0.87
|
|
62
|
Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.86
|
|
63
|
Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.
|
Drugs Aging
|
2013
|
0.86
|
|
64
|
Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.86
|
|
65
|
Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
|
Clin Adv Hematol Oncol
|
2007
|
0.86
|
|
66
|
Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review.
|
Semin Oncol
|
2011
|
0.85
|
|
67
|
Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation.
|
Transfusion
|
2011
|
0.84
|
|
68
|
Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci.
|
Biol Blood Marrow Transplant
|
2010
|
0.84
|
|
69
|
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.
|
Leuk Lymphoma
|
2004
|
0.84
|
|
70
|
Hematopoietic stem cell transplantation for myelodysplastic syndrome.
|
Biol Blood Marrow Transplant
|
2009
|
0.83
|
|
71
|
Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation.
|
Am J Blood Res
|
2011
|
0.83
|
|
72
|
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
|
Clin Lymphoma Myeloma
|
2009
|
0.83
|
|
73
|
Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
|
Am J Hematol
|
2013
|
0.82
|
|
74
|
Novel preparative regimens in hematopoietic stem cell transplantation.
|
Curr Pharm Des
|
2008
|
0.81
|
|
75
|
Cord Blood Transplantation: Can We Make it Better?
|
Front Oncol
|
2013
|
0.81
|
|
76
|
The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings.
|
Curr Hematol Malig Rep
|
2011
|
0.80
|
|
77
|
Humoral HLA sensitization matters in CBT outcome.
|
Blood
|
2011
|
0.79
|
|
78
|
Unrelated donor transplantation for acute myelogenous leukemia in first remission.
|
Biol Blood Marrow Transplant
|
2010
|
0.78
|
|
79
|
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
|
Biol Blood Marrow Transplant
|
2003
|
0.78
|
|
80
|
Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.78
|
|
81
|
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.
|
Biol Blood Marrow Transplant
|
2012
|
0.77
|
|
82
|
Advances in haploidentical stem cell transplantation.
|
Rev Bras Hematol Hemoter
|
2011
|
0.77
|
|
83
|
Strategies for widening the use of cord blood in hematopoietic stem cell transplantation.
|
Haematologica
|
2006
|
0.77
|
|
84
|
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
|
Am J Hematol
|
2013
|
0.77
|
|
85
|
Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia.
|
Curr Opin Hematol
|
2011
|
0.76
|
|
86
|
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.76
|
|
87
|
Emerging therapies in hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.76
|
|
88
|
Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
|
Expert Rev Anticancer Ther
|
2008
|
0.75
|
|
89
|
Hematopoietic stem cell transplantation for Hodgkin's disease.
|
Rev Bras Hematol Hemoter
|
2011
|
0.75
|
|
90
|
West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review.
|
Clin Infect Dis
|
2003
|
0.75
|
|
91
|
Preventing acute leukemia relapse after allogeneic transplants: how to move forward?
|
Biol Blood Marrow Transplant
|
2013
|
0.75
|
|
92
|
Sirolimus plus calcineurin inhibitors and methotrexate: is more necessarily better?
|
Leuk Lymphoma
|
2014
|
0.75
|
|
93
|
The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era.
|
Rev Bras Hematol Hemoter
|
2011
|
0.75
|
|
94
|
Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes.
|
J Natl Compr Canc Netw
|
2013
|
0.75
|
|
95
|
Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning.
|
Leuk Lymphoma
|
2011
|
0.75
|
|
96
|
Peripheral blood stem cell yield calculated using preapheresis absolute CD34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers.
|
Transfusion
|
2013
|
0.75
|
|
97
|
Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab.
|
Leuk Lymphoma
|
2003
|
0.75
|
|
98
|
Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence?
|
Clin Lymphoma Myeloma
|
2009
|
0.75
|